title: Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2.
authors.affiliation: Dermatologikum Hamburg, Hamburg, Germany.
authors.forename: Kristian
authors.initials: K
authors.lastname: Reich
authors.forename: Brad
authors.initials: B
authors.lastname: Schenkel
authors.forename: Ning
authors.initials: N
authors.lastname: Zhao
authors.forename: Philippe
authors.initials: P
authors.lastname: Szapary
authors.forename: Matthias
authors.initials: M
authors.lastname: Augustin
authors.forename: Marc
authors.initials: M
authors.lastname: Bourcier
authors.forename: Lyn
authors.initials: L
authors.lastname: Guenther
authors.forename: Richard G
authors.initials: RG
authors.lastname: Langley
mesh_terms: D000041:Absenteeism; D000328:Adult; D000704:Analysis of Variance; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D010147:Pain Measurement; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy*; D011788:Quality of Life; D012720:Severity of Illness Index; D013647:Task Performance and Analysis; D016896:Treatment Outcome; D000069549:Ustekinumab; D014937:Work
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069549:Ustekinumab